It has been recognized for decades that ERBB signaling is important in prostate cancer (PC), but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically.
It has been recognized for decades that ERBB signaling is important in prostate cancer (PC), but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically.